The stock price of Boundless Bio Inc. (NASDAQ: BOLD) has dropped by -10.71 compared to previous close of 11.30. Despite this, the company has seen a fall of -10.63% in its stock price over the last five trading days. 24/7 Wall Street reported 2024-04-07 that Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.
Is It Worth Investing in Boundless Bio Inc. (NASDAQ: BOLD) Right Now?
There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for BOLD is 11.93M, and at present, short sellers hold a 0.00% of that float. The average trading volume of BOLD on April 22, 2024 was 335.99K shares.
BOLD’s Market Performance
The simple moving average for the past 20 days is -17.87% for BOLD’s stock, with a -17.87% simple moving average for the past 200 days.
BOLD Trading at -17.87% from the 50-Day Moving Average
After a stumble in the market that brought BOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.79% of loss for the given period.
During the last 5 trading sessions, BOLD fell by -10.63%, in comparison to the 20-day moving average. In addition, Boundless Bio Inc. saw -29.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BOLD starting from RA CAPITAL MANAGEMENT, L.P., who purchase 312,500 shares at the price of $16.00 back on Apr 02 ’24. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 1,884,787 shares of Boundless Bio Inc., valued at $5,000,000 using the latest closing price.
ARCH Venture Fund IX, L.P., the 10% Owner of Boundless Bio Inc., purchase 200,000 shares at $16.00 during a trade that took place back on Apr 02 ’24, which means that ARCH Venture Fund IX, L.P. is holding 1,181,766 shares at $3,200,000 based on the most recent closing price.
Stock Fundamentals for BOLD
The total capital return value is set at -0.34.
Based on Boundless Bio Inc. (BOLD), the company’s capital structure generated 2.04 points at debt to capital in total, while cash flow to debt ratio is standing at -0.14.
Currently, EBITDA for the company is -53.84 million with net debt to EBITDA at 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.27.
Conclusion
In summary, Boundless Bio Inc. (BOLD) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
